Eli Lilly And Company ((LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: This Phase 3 study, officially titled ‘A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,’ aims to compare the efficacy and safety of pirtobrutinib against a combination of bendamustine and rituximab in patients with untreated CLL/SLL. The study’s significance lies in its potential to establish a new standard of care for these conditions.
Intervention/Treatment: The study tests two interventions: Pirtobrutinib, an oral drug, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its effectiveness as a treatment option for CLL/SLL.
Study Design: This interventional study uses a randomized, parallel assignment model without masking. Patients are randomly assigned to either the experimental group receiving Pirtobrutinib or the active comparator group receiving Bendamustine plus Rituximab. The primary purpose is treatment.
Study Timeline: The study began on September 23, 2021, and is currently active but not recruiting. The last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: The outcome of this study could significantly impact Eli Lilly and Loxo Oncology’s stock performance by potentially introducing a new treatment standard for CLL/SLL. Positive results may enhance investor sentiment, while the competitive landscape in oncology could influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.